Investor Relations
Explore information about IDEAYA's business, strategy, pipeline, and financial performance, as well as the latest updates for the investment community.
Events
Poster presentation details are below:
Author: Munoz, D. et al.
Title: IDE034, A Bispecific Antibody–Drug Conjugate Co-Targeting PTK7 and B7-H3, Exhibits Avidity-Driven Selectivity and Enhanced Antitumor Activity Versus Monospecific ADCs
Poster Number: 232
Author: Rao, A. et al.
Title: IDE892 is a highly potent and selective PRMT5 inhibitor, with MTA-positive and SAM-negative cooperativity, optimized for development in
MTAP-deleted cancers in combination with the allosteric MAT2A inhibitor IDE397
Poster Number: 4505
Author: Gupta, M. et al.
Title: The KAT6/7 inhibitor IDE574 disrupts tumor lineage identity and drug tolerance to deliver robust antitumor activity in biomarker selected indications
Poster Number: 4483